Cargando…

Incidence, prevalence and clinical outcome of anaemia in inflammatory bowel disease: a population‐based cohort study

BACKGROUND: The incidence and short‐term outcome of anaemia in inflammatory bowel disease (IBD) are largely unknown. AIM: To determine the incidence, prevalence and clinical outcome of anaemia in terms of resolution of anaemia within 12 months. We also planned to assess risk factors for anaemia in I...

Descripción completa

Detalles Bibliográficos
Autores principales:	Eriksson, Carl, Henriksson, Ida, Brus, Ole, Zhulina, Yaroslava, Nyhlin, Nils, Tysk, Curt, Montgomery, Scott, Halfvarson, Jonas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Anaemia in IBD
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6120551/ https://www.ncbi.nlm.nih.gov/pubmed/30069892 http://dx.doi.org/10.1111/apt.14920

Ejemplares similares

The management of iron deficiency in inflammatory bowel disease – an online tool developed by the RAND/UCLA appropriateness method
por: Reinisch, W, et al.
Publicado: (2013)

Comparison of intravenous low molecular weight iron dextran and intravenous iron sucrose for the correction of anaemia in pre-dialysis chronic kidney disease patients: a randomized single-centre study in Nigeria
por: Waziri, Bala, et al.
Publicado: (2016)

The rise and rise of randomized clinical evidence in Sub-Saharan Africa
por: Smyth, Brendan, et al.
Publicado: (2016)

Ferric maltol therapy for iron deficiency anaemia in patients with inflammatory bowel disease: long‐term extension data from a Phase 3 study
por: Schmidt, C., et al.
Publicado: (2016)

Impact of anaemia and the effect of empagliflozin in heart failure with reduced ejection fraction: findings from EMPEROR‐Reduced
por: Ferreira, João Pedro, et al.
Publicado: (2022)

Drug survival of anti‐TNF agents compared with vedolizumab as a second‐line biological treatment in inflammatory bowel disease: results from nationwide Swedish registers
por: Rundquist, Sara, et al.
Publicado: (2020)

Haemoglobin decreases in NSAID users over time: an analysis of two large outcome trials
por: Goldstein, J L, et al.
Publicado: (2011)

Mendelian Disease Associations Reveal Novel Insights into Inflammatory Bowel Disease
por: Han, Lichy, et al.
Publicado: (2018)

A Mobile Infliximab Dosing Calculator for Therapy Optimization in Inflammatory Bowel Disease
por: Piester, Travis, et al.
Publicado: (2018)

Risk of dementia in patients with inflammatory bowel disease: a Danish population‐based study
por: Rønnow Sand, Jakob, et al.
Publicado: (2022)

The Association Between Sustained Poor Quality of Life and Future Opioid Use in Inflammatory Bowel Disease
por: Anderson, Alyce, et al.
Publicado: (2018)

Development of the IBD Disk: A Visual Self-administered Tool for Assessing Disability in Inflammatory Bowel Diseases
por: Ghosh, Subrata, et al.
Publicado: (2017)

Lower Extremity Palpable Purpura in a Patient with Quiescent Inflammatory Bowel Disease
por: Darlington, Kimberly, et al.
Publicado: (2023)

Management of Recurrent Clostridioides Infection: A Difficile Problem in Inflammatory Bowel Disease Patients
por: Lam, Angela Y., et al.
Publicado: (2020)

Recent advances in diagnosis and treatment of microscopic colitis
por: Tysk, Curt, et al.
Publicado: (2011)

Colorectal cancer in elderly‐onset inflammatory bowel disease: a 1969–2017 Scandinavian register‐based cohort study
por: Everhov, Åsa H., et al.
Publicado: (2022)

Antidepressant medication use in Inflammatory Bowel Disease: a nationally representative population‐based study
por: Jayasooriya, Nishani, et al.
Publicado: (2022)

Cardiac energetics in patients with chronic heart failure and iron deficiency: an in‐vivo (31)P magnetic resonance spectroscopy study
por: Papalia, Francesco, et al.
Publicado: (2022)

The knowledge and skills needed to perform intestinal ultrasound for inflammatory bowel diseases—an international Delphi consensus survey
por: Madsen, Gorm Roager, et al.
Publicado: (2022)

Minor impact on fertility in men with inflammatory bowel disease: A National Cohort Study from Sweden
por: Druvefors, Emma, et al.
Publicado: (2022)

Thiopurine withdrawal during sustained clinical remission in inflammatory bowel disease: relapse and recapture rates, with predictive factors in 237 patients
por: Kennedy, N A, et al.
Publicado: (2014)

Classic drugs in the time of new drugs: real‐world, long‐term outcomes of thiopurine monotherapy in 1016 patients with inflammatory bowel disease
por: Rezazadeh Ardabili, Ashkan, et al.
Publicado: (2022)

Barriers to optimizing inflammatory bowel disease care in the United States
por: Spencer, Elizabeth A., et al.
Publicado: (2023)

Active tuberculosis in inflammatory bowel disease patients: a case–control study
por: Freitas Cardoso de Azevedo, Matheus, et al.
Publicado: (2023)

Predictive factors of response to infliximab therapy in Brazilian inflammatory bowel disease patients
por: Martins, Camilla de Almeida, et al.
Publicado: (2023)

The Gut Microbiota in Collagenous Colitis Shares Characteristics With Inflammatory Bowel Disease-Associated Dysbiosis
por: Carstens, Adam, et al.
Publicado: (2019)

Barriers in inflammatory bowel disease care in Central and Eastern Europe: a region-specific analysis
por: Prokopič, Michal, et al.
Publicado: (2023)

IBD LIVE Case Series–Case 2: Previous Cancer in a Patient with Crohn's Disease: Is It Appropriate to Use Biologics and Immunosuppressants for IBD Treatment?
por: Le, Peter N., et al.
Publicado: (2015)

Outcomes of Pregnancies With Maternal/Paternal Exposure in the Tofacitinib Safety Databases for Ulcerative Colitis
por: Mahadevan, Uma, et al.
Publicado: (2018)

Infliximab for Crohn’s Disease: More Than 13 Years of Real-world Experience
por: Lichtenstein, Gary R, et al.
Publicado: (2018)

What Is the Risk of Progressive Multifocal Leukoencephalopathy in Patients With Ulcerative Colitis or Crohn’s Disease Treated With Vedolizumab?
por: Card, Timothy, et al.
Publicado: (2018)

Communication Between Physicians and Patients with Ulcerative Colitis: Reflections and Insights from a Qualitative Study of In-Office Patient–Physician Visits
por: Rubin, David T., et al.
Publicado: (2017)

Real‐world experience of switching from intravenous to subcutaneous vedolizumab maintenance treatment for inflammatory bowel diseases
por: Volkers, Adriaan, et al.
Publicado: (2022)

Diagnosis and management of microscopic colitis: current perspectives
por: Bohr, Johan, et al.
Publicado: (2014)

Risk factors for thiopurine‐induced myelosuppression and infections in inflammatory bowel disease patients with a normal TPMT genotype
por: Broekman, M. M. T. J., et al.
Publicado: (2017)

The inexorable increase of biologic exposure in paediatric inflammatory bowel disease: a Scottish, population‐based, longitudinal study
por: Burgess, Christopher J., et al.
Publicado: (2022)

Harnessing Regulatory T Cells for the Treatment of Inflammatory Bowel Disease
por: Geem, Duke, et al.
Publicado: (2015)

Polymorphism in the Retinoic Acid Metabolizing Enzyme CYP26B1 and the Development of Crohn’s Disease
por: Fransén, Karin, et al.
Publicado: (2013)

Going Viral: Management of IBD in the Era of the COVID-19 Pandemic
por: Gutin, Liat S., et al.
Publicado: (2020)

Opportunistic Knocks: A Gardener with Ulcerative Colitis and New Pulmonary Nodules
por: Canakis, Andrew, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_up1dvfeqqhqpkevuab94ji2mdk